<DOC>
	<DOCNO>NCT00879658</DOCNO>
	<brief_summary>The purpose study determine dose-response curve MRI-based efficacy BAF312 compare placebo patient Relapsing-Remitting Multiple Sclerosis ( RRMS ) , characterize safety tolerability selection optimal dose late phase III study . Study Design Rationale An adaptive design choose characterize dose response curve BAF312 . In first period study ( `` Period 1 '' ) , three dos BAF312 placebo test MRI efficacy . Based interim analysis ( IA ) 3 month treatment , two additional active dos period 2 select , thus allow optimize overall determination dose response curve 5 data point active treatment , placebo . The dos keep blind . The use Modeling Simulation allow establish full range dynamic dose-response curve silico , hence definition optimal dose later phase III study . The choice placebo treatment control essential obtain information specific compare non-specific effect active treatment provide best way evaluate efficacy assess true safety tolerability profile BAF312 . Short-term placebo exposure ( 6 ( Period 1 ) 3 ( Period 2 ) month , respectively ) unlikely lead long term difference outcomes [ Polman , 2008 ] . The use adaptive design strategy contribute significant reduction placebo exposure , term number patient duration , compare conventional trial model . Patients complete study within protocol may eligible Extension Phase study receive long-term BAF312 treatment ( separate protocol ) .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Optimal Dose Finding Study BAF312 Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Diagnosis Multiple Sclerosis ( MS ) define revise McDonald criterion . A relapsingremitting course disease least 1 document relapse previous year , 2 document relapse previous 2 year , positive gadolinium ( Gd ) enhance MRI scan screening ( case first MRI scan obtain screen negative , second scan may obtain 1 month later . ) An Expanded Disability Status Scale ( EDSS ) score 05.0 inclusive randomization . Neurologically stable evidence relapse corticosteroid treatment within 30 day prior randomization . Patients decline initiation continuation treatment available disease modify drug MS , whatever reason , inform respective benefit possible adverse event investigator . A manifestation another type MS RRMS History chronic disease immune system MS Malignancies , diabetes , significant cardiovascular , pulmonary hepatic disease condition Active infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>Demyelinating Autoimmune Diseases</keyword>
</DOC>